GENB · NASDAQ
Generate Biomedicines (GENB) Stock Price & Fundamentals
Generate Biomedicines (GENB) closed at $273.08 on Oct 9, 2026, up 0.09% from the previous close of $272.84.
Share price, past year
1Y +34.51%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $273.08 |
| Sep 30, 2026 | $272.63 |
| Aug 31, 2026 | $262.16 |
| Jul 31, 2026 | $241.54 |
| Jun 30, 2026 | $233.90 |
| May 29, 2026 | $245.81 |
| Apr 30, 2026 | $235.19 |
| Mar 31, 2026 | $227.53 |
| Feb 27, 2026 | $231.70 |
| Jan 30, 2026 | $224.23 |
| Dec 31, 2025 | $204.58 |
| Nov 28, 2025 | $208.37 |
| Oct 31, 2025 | $195.52 |
Key statistics
- 52-week range
- $195.52 – $273.08
Financials
Generate Biomedicines's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Company profile
- Name
- Generate Biomedicines, Inc.
- Ticker
- GENB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 101 South Street, Suite 900, Somerville, MA 02143
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002100782
Recent SEC filings
- Aug 26, 2026
- Aug 6, 2026
- Aug 6, 2026
- May 7, 2026
- May 7, 2026
- Mar 2, 2026
Frequently asked questions
What is Generate Biomedicines's stock price?
Generate Biomedicines (GENB) closed at $273.08 on Oct 9, 2026, up 0.09% from the previous close of $272.84.
Sources and methodology
Fundamentals come from Generate Biomedicines, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures